| 2025 | 2024 | 2023 | ||||
|---|---|---|---|---|---|---|
| Gross margin | 738,0 k € | +1392.9% | -57,1 k € | -941.9% | -5,5 k € | |
| EBITDA | 75,8 k € | +231.5% | -57,6 k € | -951.9% | -5,5 k € | |
| Operating profit | 75,8 k € | +231.5% | -57,6 k € | -951.9% | -5,5 k € | |
| Profit/loss | 76,9 k € | +435.9% | 14,3 k € | -43.2% | 25,3 k € | |
| Equity | 2,1 M € | +3.8% | 2,0 M € | +0.7% | 2,0 M € | |
| Total assets | 2,6 M € | +21.8% | 2,1 M € | +3.8% | 2,0 M € | |
| Debts | 418,4 k € | +489.3% | 71,0 k € | +742.7% | 8,4 k € | |
| Staff | 2,5 | — | — | |||
Source: Belgian Official Gazette
Public limited company · Machelen (Brab.) · incorporated on 19/01/2023 · 2,5 ETP
Public limited company profitable and well capitalised.
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
Key indicators
MENARINI STEMLINE BENELUX NV/SA is a Public limited company incorporated in 2023. Its main activity is: Wholesale of pharmaceutical goods. Its registered office is in Machelen (Brab.). It employs on average 2,5 ETP workers (FTE).